ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.

Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights.

Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® (trade name EURneffy^® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

Monique Allaire
THRUST
monique@thrustsc.com

Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com

FAQ

When will ARS Pharmaceuticals (SPRY) report Q3 2025 results and hold its conference call?

The conference call and webcast are scheduled for Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET.

How can I join the ARS Pharmaceuticals (SPRY) November 10, 2025 webcast?

Register to obtain dial-in information and access the live webcast and slides on the company’s Events & Presentations page in Investors & Media.

Will ARS Pharmaceuticals (SPRY) make the Q3 2025 webcast available after the live event?

Yes. A replay of the webcast will be available for 30 days following the event.

What topics will ARS Pharmaceuticals (SPRY) cover on the November 10, 2025 call?

The company will discuss its third quarter 2025 financial results and business highlights.

Where can investors find slides and materials for the ARS Pharmaceuticals (SPRY) Q3 2025 presentation?

Slides and webcast materials will be posted on the company’s Investors & Media > Events & Presentations page.